Two decades of hepatitis B infections among drug users in amsterdam: Are they still a high-risk group?

Journal of Medical Virology

Volumn 81, Issue 7, 2009, Pages 1163-1169

  Van Houdt, Robin ^a   Van Den Berg, Charlotte H S B ^a,b   Stolte, Ineke G ^a   Bruisten, Sylvia M ^a,b   Dukers, Nicole H T M ^a,c   Bakker, Margreet ^b   Wolthers, Katja C ^b   Prins, Maria ^a,b   Coutinho, Roel A ^b,d  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c South Limburg Public Health Service   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Drug users; Genotypes; Hepatitis B; Incidence; Risk factors

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B ANTIBODY; VIRUS DNA;

ACUTE HEPATITIS; ADULT; ARTICLE; DRUG ABUSE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NONHUMAN; NUCLEOTIDE SEQUENCE; POISSON DISTRIBUTION; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SEROTYPE; TREND STUDY; VIRUS STRAIN; BLOOD; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; DRUG USE; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PHYLOGENY;

HEPATITIS B VIRUS;

ADULT; CLUSTER ANALYSIS; DNA, VIRAL; DRUG USERS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; INCIDENCE; MALE; MOLECULAR SEQUENCE DATA; NETHERLANDS; PHYLOGENY; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 67650001533     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21504     Document Type: Article

References (19)

1. De Wit GA, Kretzschmar MEE, Smits LJM, Struijs JN, Postma MJ, Van de Laar MJW, Jager JC. 2000. Cost-effectiveness of national hepatitis B vaccination: Interim report. 2000. Bilthoven: National institute of public health and the environment (RIVM): Report 403505 004.
2. Fisker NF, Pedersen CF, Lange MF, Nguyen NT, Nguyen KT, Georgsen J, Christensen PB. 2004. Molecular epidemiology of hepatitis B virus infections in Denmark. J Clin Virol 31:46-52.
3. Garfein RS, Bower WA, Loney CM, Hutin YJ, Xia GL, Jawanda J, Groom AV, Nainan OV, Murphy JS, Bell BP. 2004. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 40:865-873.
4. Hall TA. 1999. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95-98.
5. Kumar S, Tamura K, Nei M. 2004. MEGA 3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 5:150-163.
6. Levine OS, Vlahov D, Brookmeyer R, Cohn S, Nelson KE. 1996. Differences in the incidence of hepatitis B and human immunode-ficiency virus infections among injecting drug users. J Infect Dis 173:579-583.
7. Lindenburg CE, Krol A, Smit C, Buster MC, Coutinho RA, Prins M. 2006. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: A 19-year prospective cohort study. AIDS 20:1771-1775.
8. Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais D. 2007. Sexual and other noninjection risks for HBV and HCVseroconversions among noninjecting heroin users. J InfectDis 195:1052-1061.
9. Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO. 1992. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 73:1201-1208.
10. Ruan Y,Qin G, Yin L, ChenK,Qian HZ, Hao C, Liang S, Zhu J, Xing H, Hong K, Shao Y. 2007. Incidence of HIV, hepatitisC and hepatitis B viruses among injection drug users in southwestern China:A3-year follow-up study. AIDS 21:S39-S46.
11. Van den Berg CHSB, Smit C, Bakker M, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M. 2007. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 22:183-193.
12. Van den Hoek JA, Coutinho RA, Van Haastrecht HJ, Van Zadelhoff AW,Goudsmit J. 1988.Prevalence and risk factors ofHIVinfections among drug users and drug-using prostitutes in Amsterdam. AIDS 2:55-60.
13. Van Houdt R, Sonder GJ, Dukers NHTM, Bovee LPMJ, Van den Hoek JAR, Coutinho RA, Bruisten SM. 2007a. Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands. Vaccine 25:2698-2705.
14. Van Houdt R, Bruisten SM, Koedijk FD, Dukers NHTM, Op de Coul ELM, Mostert M, Niesters HG, Richardus JH, De Man GA, Van Doornum GJJ, Van den Hoek JAR, Coutinho RA, Van de Laar MJW, Boot HJ. 2007b.Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: Nationwide survey. J Med Virol 79:895-901.
15. Van Laar MW, Cruts AA, Verdurmen JE, Van Ooyen-Houben MM, Meijer RF. 2007. Nationale Drug Monitor, jaarbericht 2006.
16. Van Marrewijk CM, Veldhuijzen IK, Conyn-Van Spaendonk MA, Kooy H, Van den Hof S, Dorigo-Zetsma JW. 1999. Prevalence of hepatitis B viral markers in the Dutch population: A population-based serosurveillance study (Pienter project). Bilthoven: National institute for public health and the environment (RIVM), report 243680 001.
17. Van Steenbergen JE, Niesters HG, Op de Coul EL, Van Doornum GJ, Osterhaus AD, Leentvaart-Kuijpers AF, Coutinho RA, Van den Hoek JA. 2002. Molecular epidemiology of hepatitis B virus in Amsterdam 1992-1997. J Med Virol 66:159-165.
18. WHO. 2008. Hepatitis B fact sheet 204. Available at: http:// www.who.int/mediacentre/factsheets/fs204/en/index.html.Accessed February 11, 2008.
19. Yates S. 2002. HBV load in treated and untreated individuals. Enschede: Febodruk BV. pp 91-107.